Comparative Effectiveness of Risankizumab vs Other Biologics in Crohn’s Disease: Long-Term and Quality-of-Life Outcomes after Inadequate Response to Prior Therapy
Introduction and Purpose: Crohn’s disease (CD) is a chronic inflammatory condition with an unpredictable course. Despite the availability of biologics, many patients fail to achieve sustained remission. Risankizumab, an anti-IL-23 p19 monoclonal antibody, offers a new therapeutic option. This stu...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2025-05-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/59986 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|